These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16234156)

  • 1. Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole.
    Attilakos G; Fox R
    J Obstet Gynaecol; 2005 Aug; 25(6):609-10. PubMed ID: 16234156
    [No Abstract]   [Full Text] [Related]  

  • 2. Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
    Van Calster B; Van Ginderachter J; Vlasselaer J; Van de Putte G; Berteloot P; Timmerman D; Depypere H; Blomme C; Vlaemynck G; De Jonge E; Van den Broecke R; Vergote I; Amant F; Van Huffel S; Neven P
    Menopause; 2011 Feb; 18(2):224-9. PubMed ID: 20881891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World's largest breast cancer treatment trial supports anastrozole use.
    Oncology (Williston Park); 2002 Jan; 16(1):63. PubMed ID: 11831610
    [No Abstract]   [Full Text] [Related]  

  • 4. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
    Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
    Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The uterine sarcoma, a new risk identified for tamoxifen].
    Baron M; Dessogne P; d'Anjou J
    Presse Med; 2004 Mar; 33(5):321-2. PubMed ID: 15041879
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma Doppler blood flow in patients scheduled for hysterectomy: a pilot study.
    Brito LG; Candido-dos-Reis FJ; Magario FA; Sabino-de-Freitas MM
    Ultrasound Obstet Gynecol; 2012 Jul; 40(1):119-20. PubMed ID: 22102490
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Panasci LC
    J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331341
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.
    Hilário SG; Bozzini N; Borsari R; Baracat EC
    Fertil Steril; 2009 Jan; 91(1):240-3. PubMed ID: 18249392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata -- a pilot study.
    Sadan O; Ginath S; Sofer D; Rotmensch S; Debby A; Glezerman M; Zakut H
    Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):183-6. PubMed ID: 11384804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
    Prescrire Int; 2001 Jun; 10(53):76-7. PubMed ID: 11718168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
    Boccardo F; Guglielmini P; Bordonaro R; Fini A; Massidda B; Porpiglia M; Roagna R; Serra P; Orzalesi L; Ucci G; Rubagotti A
    Eur J Cancer; 2013 May; 49(7):1546-54. PubMed ID: 23415888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
    Bruntsch U
    MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
    [No Abstract]   [Full Text] [Related]  

  • 15. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
    Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitotically active leiomyoma of the uterus in a postmenopausal breast cancer patient receiving tamoxifen.
    Liu IF; Yen YS; Cheng YM; Chou CY
    Taiwan J Obstet Gynecol; 2006 Jun; 45(2):167-9. PubMed ID: 17197361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapeutic prophylaxis of gynecomastia.
    Thönnessen D; Wenz F
    J Clin Oncol; 2005 Aug; 23(24):5845; author reply 5846-7. PubMed ID: 16110041
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Bergmann L
    Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.